help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LEE, E.
Right arrow Articles by KILFEATHER, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEE, E.
Right arrow Articles by KILFEATHER, S.

Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1881-1886

Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals

ELAINE LEE, TRACY ROBERTSON, JACQUELINE SMITH, and STEPHEN KILFEATHER

Institute for Cardiovascular and Respiratory Pharmaceutical Development, School of Sciences, University of Sunderland, Sunderland, United Kingdom

Eosinophilia is a feature of airway inflammation associated with asthma. Leukotriene antagonists provide therapeutic benefit in asthma, but their potential antiinflammatory actions have not been fully explored. We have examined the role of eosinophil-derived cysteinyl leukotrienes in the maintenance of eosinophil survival, and the involvement of leukotrienes in the paracrine stimulation of eosinophil survival by mast cells and lymphocytes. We obtained eosinophils and autologous lymphocytes from peripheral blood of asthmatic subjects. Leukotriene (LT)-B4, LTC4 and LTD4, granulocyte-macrophage colony-stimulating factor (GM-CSF), and fibronectin promoted eosinophil survival. LTD4 (10-6 M) was as effective as GM-CSF (5 ng/ml) and fibronectin (400 ng/ml) in promoting survival. Lymphocytes and conditioned medium from a human mast cell line (HMC-1) induced eosinophil survival. Blockade of cysteinyl leukotriene receptors with SKF 104353 (pobilukast, 3 nM), and inhibition of 5-lipoxygenase (5-LO) with BW A4C (1 µM) and of 5-LO activating protein with MK 886 (1 µM), all increased basal rates of eosinophil apoptosis and reversed GM-CSF-induced eosinophil survival. Fifty percent reversal of GM-CSF- induced survival was achieved with SKF 104353 at 0.3 nM. The potency of SKF 104353 was two orders of magnitude greater than that of the LTB4 receptor antagonist SB 201146. Mast cell- and lymphocyte-induced eosinophil survival were completely reversed by SB 201146, SKF 104353, BW A4C, and MK 886. These findings provide evidence for the involvement of an autocrine cysteinyl leukotriene pathway that supports eosinophil survival in response to a range of survival stimuli. They also suggest that LTB4 could act as a paracrine stimulus of eosinophil survival.




This article has been cited by other articles:


Home page
 NEJMHome page
M. Peters-Golden and W. R. Henderson Jr.
Leukotrienes
N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Farahi, A. S. Cowburn, P. D. Upton, J. Deighton, A. Sobolewski, E. Gherardi, N. W. Morrell, and E. R. Chilvers
Eotaxin-1/CC Chemokine Ligand 11: A Novel Eosinophil Survival Factor Secreted by Human Pulmonary Artery Endothelial Cells
J. Immunol., July 15, 2007; 179(2): 1264 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. R. Henderson Jr., G. K. S. Chiang, Y.-t. Tien, and E. Y. Chi
Reversal of Allergen-induced Airway Remodeling by CysLT1 Receptor Blockade
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 718 - 728.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. Busse and M. Kraft
Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy
Chest, April 1, 2005; 127(4): 1312 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Peters-Golden, C. Canetti, P. Mancuso, and M. J. Coffey
Leukotrienes: Underappreciated Mediators of Innate Immune Responses
J. Immunol., January 15, 2005; 174(2): 589 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave
Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma
Eur. Respir. J., January 1, 2005; 25(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes
Mediators of Chronic Obstructive Pulmonary Disease
Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. Parameswaran, R. Watson, G. M. Gauvreau, R. Sehmi, and P. M. O'Byrne
The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma
Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 915 - 920.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. C. Yopp, G. J. Randolph, and J. S. Bromberg
Leukotrienes, Sphingolipids, and Leukocyte Trafficking
J. Immunol., July 1, 2003; 171(1): 5 - 10.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Triggiani, F. Granata, B. Balestrieri, A. Petraroli, G. Scalia, L. Del Vecchio, and G. Marone
Secretory Phospholipases A2 Activate Selective Functions in Human Eosinophils
J. Immunol., March 15, 2003; 170(6): 3279 - 3288.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Z. Csoma, S. A. Kharitonov, B. Balint, A. Bush, N. M. Wilson, and P. J. Barnes
Increased Leukotrienes in Exhaled Breath Condensate in Childhood Asthma
Am. J. Respir. Crit. Care Med., November 15, 2002; 166(10): 1345 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
C. Bandeira-Melo, L. J. Woods, M. Phoofolo, and P. F. Weller
Intracrine Cysteinyl Leukotriene Receptor-mediated Signaling of Eosinophil Vesicular Transport-mediated Interleukin-4 Secretion
J. Exp. Med., September 16, 2002; 196(6): 841 - 850.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Minoguchi, Y. Kohno, H. Minoguchi, N. Kihara, Y. Sano, H. Yasuhara, and M. Adachi
Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast
Chest, March 1, 2002; 121(3): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. PETERS-GOLDEN, M. BAILIE, T. MARSHALL, C. WILKE, S. H. PHAN, G. B. TOEWS, and B. B. MOORE
Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice
Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 229 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. H. P. Oliveira, C. M. Hogaboam, A. Berlin, and N. W. Lukacs
SCF-induced airway hyperreactivity is dependent on leukotriene production
Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1242 - L1249.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Bandeira-Melo, M. Phoofolo, and P. F. Weller
Extranuclear Lipid Bodies, Elicited by CCR3-mediated Signaling Pathways, Are the Sites of Chemokine-enhanced Leukotriene C4 Production in Eosinophils and Basophils
J. Biol. Chem., June 15, 2001; 276(25): 22779 - 22787.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  SOTA, FL